Global DPT vaccine Market 2020 Analysis By Manufacturers, Latest Trends, Competitive Landscape And Strategies

 Global Diphtheria Tetanus and Pertussis (DPT) vaccine Market - Overview

The Global DPT vaccine Market is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.

There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1357 

Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.

However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.

Global DPT vaccine Market - Regional Analysis

Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.

The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.

Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.

Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.

The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.

Global DPT vaccine Market - Company Analysis

Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.

Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.

Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others are some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis. 

Browse More Details of the Report@ https://www.marketresearchfuture.com/reports/dpt-vaccine-market-1357

Worldwide Ovulation Test Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2025

 

Global Ovulation Test Market - Overview

Ovulation is the biological process that results in the release of eggs from the ovary. The ovulation test detects a rise in luteinizing hormone (LH) in the urine. This rise in the hormone signals the ovary to release the egg. This test is often used by women to help predict when an egg release is likely. This is when pregnancy is most likely to occur. Moreover, these ovulation prediction kits or OPKs are also being used to detect the exact day of ovulation for those women that undergo a treatment for infertility. There is an increase in the demand of ovulation test kits across the globe. Urine test segment accounts for the largest market share due to its extensive application by women for testing pregnancy.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1341 

The global ovulation test market is growing with the steady pace. The global ovulation test market is expected to grow at a CAGR of ~4.5% during the forecast period 2017-2023. According to a recent study report published by the Market Research Future, The global ovulation test market is booming and expected to gain prominence over the forecast period growing rapidly due to rising technology driven ovulation monitors. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).

The market is expected grow with the same trends during the forecast period. The major drivers will be technological advancement for reliable and accurate results from ovulation test kits has spurred the growth the market.  According to the Centers for Disease Control, one in eight women has trouble conceiving or sustaining a pregnancy, due to age, health issues or other factors. For that, companies are introducing advanced kits which will help them to monitor their pregnancy and ovulations. For instance, apps like Glow and Apple's own Reproductive Health kit in iOS make it easier to record, visualize and aggregate large amounts of data related to the reproductive health of the patients.  Moreover, pregnancy management and women and child health gaining importance throughout the world favor the growth of this market. Increase in first pregnancy, complications during pregnancy and demand of reliable technology for pregnancy test kits.

Global Ovulation Test Market - Competitive Analysis

The market for ovulation test is characterised by the presence of several well-established and small players, the global market of ovulation test appears to be getting competitive in this region due to increasing first time pregnancy age and gynaecological disorders. Global players are increasingly expanding their footprint in the emerging nations, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to increase with time during the forecast period. Well established players are entering into new product launches in order to gain competitive edge in this market and to maintain their market position.    

Companies like in April 2016, Church & Dwight Co., Inc. has launched a First Response Pregnancy PRO Digital Pregnancy Test + App Access. It is the first and only Bluetooth enabled pregnancy test stick which will be available nationwide. This will help the company add-on a product to their portfolio and help to increase the customer base.

Moreover, Prestige Brands Holdings Inc., in December 2016, has announced to acquire C.B Fleet Company which manufactures products for feminine care to reach in global market.   Furthermore, Swiss Precision Diagnostics a market leader across the globe with wide range of women health brands out of which Accu clear provides a range of products for pregnancy and ovulation test. It has been granted three patents by the U.S. in advanced clear blue ovulation test helping it to maintain its leading position in the market.

This particular market is focussing on product launches and acquisitions as a key strategy, thereby presenting a potential opportunities for the growth of the market.

Swiss Precision Diagnostics GmbH (Switzerland), Church & Dwight Co. Inc. (U.S.), Prestige Brands Holdings Inc. (U.S.), HiLin Life Products Inc. (U.S.) and Fairhaven Health LLC (U.S.). Other players in this market are: Fertility Focus Limited (U.K.), Geratherm Medical AG (Germany), Accuquik (California), NecLife (India) and Piramal Healthcare (India) are some of the prominent players at the forefront of competition in the Global Ovulation Test Market and are profiled in MRFR Analysis. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ovulation-test-market-1341

Biosimilars Market Overview By Trends, Industry Top Manufactures, Size, Industry Growth Analysis & Forecast Till 2025

 Biosimilars Market Scenario

Biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1329 

For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.

For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)

Biosimilars Market Segmentation

Global Biosimilars Market has been segmented based on product, applications, end users, and region.

The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.

The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin

The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  

For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.

On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.

For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.

Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.

Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.

The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Biosimilars Market Key Players

The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).

Regional Market Summary

The market in Europe is expected to dominate the global biosimilars market due to the increasing biosimilar product approvals and the emergence of new market participants in the region. The growing prevalence of chronic diseases in the US and Canada is expected to drive the market growth. Furthermore, there has been an increase in the expenditure in research by healthcare bodies; this is expected to fuel the growth of the market in this region. For example, according to Amgen, in 2019, Europe has an advanced biosimilar market, with 53 approved biosimilar products. The market in Asia-Pacific expected to show a considerable amount of growth. This can be attributed to the patent expiry of biologic products, introduction of new biosimilars, adoption of biosimilars to reduce the treatment cost, and the involvement of key companies. For instance, according to the National Center for Biotechnology Information, in 2019, Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop similar biologics. Already there are more than 100 Indian biopharmaceutical companies are engaged in manufacturing and marketing of biosimilar. The market in Americas is projected to have a steady growth rate during the forecast period owing to an increase in chronic diseases and well-developed healthcare system. The market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329 

World Erectile Dysfunction Drugs Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

 Erectile Dysfunction Drugs Market Overview: 

The global market for erectile dysfunction drugs market is set to cross a valuation of USD 2930million by 2023 with a CAGR of 3.5% during the forecast period (2018-2023). Market Research Future revealed several factors like a rising recording of cases of erectile disorder, increasing geriatric population, expiry of patents of major blockbuster drugs, and better drug development as major reasons behind the growth of the erectile dysfunction drugs market. Growth in the sedentary lifestyle may also boost the demand for such drugs.  

However, patients often fail to adhere to these drugs in proper terms, which can restrain the growth of this erectile dysfunction drug market growth.  

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1313

Erectile Dysfunction Drugs Market Segmentation: 

The global erectile dysfunction drugs market, on account of MRFR experts, has been segmented based on drugs and end users. This segmentation is expected to reveal insight related to dynamics, growth factors, and demographic challenges. These insights will be further backed by figures received after detailed analysis.  

By drug, the global market on the erectile dysfunction drugs has been segmented into Cialis (tadalafil), staxyn/Levitra (vardenafil), viagra (sildenafil citrate), zydena (udenafil), vitaros (alprostadil cream), stendra/spedra (avanafil), and others. Viagra has a huge market share as it is the first-of-its-kind drug that received the approval of the FDA in 1998. Cialis is expected to make a better impact on the market in terms of growth as its erection period is higher than that of Viagra.  

By end user, the global market for erectile dysfunction drugs has been segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is expected to benefit from the easy availability of drugs. The segment is the largest one. Hospitals are expected to gain more from growing awareness and are expected to be the fastest one in terms of growth.  

Erectile Dysfunction Drugs Market Regional Analysis: 

The Americas are set to dominate the global erectile dysfunction drugs market. This is primarily due to the rising presence of major drug companies and the increasing adoption of various new technologies to treat the disorder. Also, the growing awareness regarding the disorder is expected to boost the market profit. In Asia Pacific, rising awareness and the massive population are expected to play in favor of the market.  

Erectile Dysfunction Drugs Market Competitive Landscape: 

Global erectile dysfunction drugs market is expected to get boosted by the strategic developments launched by companies like Apricus Biosciences Inc., Bayer AG, Pfizer, Inc., Dong-A Pharmaceutical Co. Ltd., Cristalia Produtos Quimicos Farmaceuticos Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Vivus, Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and others. These companies are showing an intent to take the global market forward by constantly indulging in various strategic discussions where they are working on mergers, acquisitions, collaborations, hike in investment for research and development, branding strategies, distribution channels, and others. MRFR’s recording of all the latest proceedings is expected to improve the scope of market study.  

Industry News: 

In May 2020, a report revealed that the global market for erectile dysfunction drugs market had witnessed a price fall in both generic and branded drugs between July 2019 and January 2020. But the price of branded drugs has bounced back after February 2020. The report is on the basis of a close analysis of several online drug supply chain. One of the major reasons behind this price change is COVID-19. The rise in home delivery services has changed the market expectations and the price is getting impacted by that.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

...Continued 

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313 

Neuroendoscopy Market Report By Global Industry Trends And Forecast The Upcoming Opportunities And Demand Till 2023

 Global Neuroendoscopy Market Statistics and Analysis, by Product (Rigid, Flexible Neuroendoscopes), by Application (Transnasal, Intraventricular, Transcranial Neuroendoscopy), by Usability (Reusable, Disposable), End-User (Hospitals) – Global Forecast Till 2023

Market Scenario:

Neuroendoscopy is characterized as a minimally-invasive surgical procedure which is extensively utilized to remove tumors. The excision occurs via small holes present in the skull, i.e., through the mouth or nose. In neuroendoscopy procedures, a small telescopic device equipped with a high-resolution video camera and an eyepiece is used. This gives the neurosurgeons, an ability to navigate and effectively access the parts of the brain that could not be addressed by traditional surgery. Some of the other advantages of neuroendoscopy include fast recovery, minimal scarring, and others.

The increasing prevalence of brain tumors is a major driver for the market growth. According to a study published by the Neuro-Oncology Journal in 2015, the global incidence rate for all types of brain tumors was estimated to be about 10.82 per 100 000 persons.

The increasing prevalence of brain tumors, increasing demand for minimally invasive surgical procedures, growing geriatric population, and favorable reimbursement policies are estimated to drive the global neuroendoscopy market growth, during the forecast period. However, a dearth of physicians and the high cost of neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period.

Global Neuroendoscopy Market is expected to grow at an approximate CAGR of 5.2% during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5836

According to the National Institute of Health in 2016, the global geriatric population is estimated to be more than triple from 2015 to 2050, i.e., it is projected to grow from 126.5 in 2015 million and reach 446.6 million by 2050. However, a shortage of physicians and high cost for neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period. The Association of American Medical Colleges in 2016 stated that the demand for physicians continued to grow at a higher rate, exceeding the supply. The projected total physician shortfall by 2025 is estimated to be in between 61,700 and 94,700.

Key players

The key players in the global neuroendoscopy market are KARL STORZ (Germany), B. Braun (Germany), Ackermann Instrumente (Germany), Adeor Medical (Germany), Hangzhou Hawk Optical Electronic Instruments (China), Machida Endoscope (Japan), Tonglu Wanhe Medical Instrument (China), Schindler Endoskopie (Germany), Clarus Medical (U.S.), LocaMed (U.K), Visionsense Corporation (U.S.), Olympus Corporation (Japan), Zeiss International (Germany), Stryker (U.S.), Medtronic (U.S.), and others.

Segmentation

The global Neuroendoscopy market is segmented on the basis of product, application, usability, and end-user.

On the basis of products, the market is segmented into rigid neuroendoscopes and flexible neuroendoscopes. The rigid neuroendoscopes segment is sub-segmented into rigid video scopes and rigid fiberscopes. On the basis of application, the market is categorized into transnasal neuroendoscopy, intraventricular neuroendoscopy, and transcranial neuro-endoscopy. On the basis of usability, the market is segmented into reusable neuroendoscopes and disposable neuroendoscopes. On the basis of end-users, the market is segmented into hospitals, clinics, medical research centers, and others.

Regional Analysis

The Americas dominates the global neuroendoscopy market. Factors such as the increasing prevalence of brain tumors, the presence of a well-developed healthcare sector, and huge health care expenditures within the region drive the market growth within the region. Moreover, the presence of key players such as Stryker and Medtronic, besides others and the growing geriatric population within the region fuel the market growth.

Europe stands second in the global neuroendoscopy market due to the increasing demand for minimally invasive surgeries, rising availability of funds for research and development, and a huge patient population. According to the Cancer Research U.K., the total number of new cases for brain tumor was estimated to be about 11,432 in 2015.  

Followed by Europe, Asia Pacific stands third in the global neuroendoscopy market. Moreover, the region is projected to be the fastest growing region in the global market. This can be attributed to the presence of developing economies such as China, growing patient population, developing healthcare sector, and increasing per capita healthcare expenditures. Additionally, favorable government policies support the market growth. Medical tourism and rising geriatric population are estimated to fuel the market growth. According to the Indian Brand Equity Foundation, the medical tourism industry in India is estimated to grow rapidly and reach USD 9 billion by 2020.

The Middle East and Africa holds the least share in the global neuroendoscopy market due to the presence of poor economies, stringent government policies, lack of awareness, low per capita income, and poor availability of healthcare services, especially within the African region. A majority of the neuroendoscopy market within the region is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure.

Browse More Medical Device Reports @  https://www.marketresearchfuture.com/reports/neuroendoscopy-market-5836

The Picture Archiving and Communication System (PACS) Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 Market Scenario:

Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           

Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.

It is noted that the increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the PACS market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.

Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5833

Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.

It is estimated that the Picture Archiving and Communications Systems (PACS) market size is expected to boost at a CAGR 7.0% during the forecast period of 2017–2023.

Key Players

Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others

Segmentation

The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.

On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.

On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.

On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.

On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.

On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.

Regional Analysis

Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.

The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.

Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.

The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/picture-archiving-communications-systems-market-5833

Cord Blood Banking Services Market Forecasts By Industry Drivers, Regions Till 2023

 Market Scenario:

The global cord blood banking services market is expected to exhibit a robust 11.4% CAGR over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global cord blood baking services market is likely to be driven by the growing research into the medical utility of stem cells and cord blood, and the growing establishment of the infrastructure required to create a strong cord blood banking services network.

The umbilical cord blood is a rich source of stem cells and can treat more than 80 genetic diseases. The stem cells also can treat long-lasting diseases such as diabetes, cancer, immune diseases, and blood diseases. Even though a small amount of cord blood can be collected from a single umbilical cord, it comprises a large number of stem cells which can be cultivated and stored for the future use. These cells are collected from hospitals and nursing homes after delivery and stored in cord blood banks (average of 20–25 years) for future use.

Currently, the companies are trying to intensify the awareness about the benefits of cord blood storage. For instance, in 2014, the Institute for Transfusion Medicine and Cord Blood Registry pooled their resources to launch a multi-year initiative for increasing the awareness of cord blood cells.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5817

Factors such as increasing application of cord blood in the treatment of chronic conditions, increasing the focus of federal agencies to set up public banking units, growing awareness regarding this treatment line, and increasing number of facilities across the region are driving the market growth. However, the high cost and probability of non-usage, along with the recommendation driven market by gynecologists are factors hampering the of the Cord Blood Banking Services market growth.

Key Players

Some of the key players in the global cord blood banking services market are China Cord Blood Corporation (China), Cord Blood America, Inc. (U.S.), CBR Systems, Inc. (U.S.), Cordlife Group Limited (Singapore), Cryo-Cell International, Inc. (U.S.), Cryo-Save AG (Netherland), ViaCord, Inc. (U.S.), Virgin Health Bank (Qatar), California Cryobank Stem Cell Services LLC (U.S.), StemCyte, Inc. (India), Norton Healthcare, Inc. (U.S.), Lifeforce Cryobank Sciences Inc. (U.S.), CordVida (Brazil), CryoHoldco de Latinoamerica, S.A.P.I. De C.V. (Mexico), Vita 34 International (Germany), Maze Cord Blood Laboratories (U.S.), The University of Colorado Cord Blood Bank (U.S.), CorCell (U.S.), Lifebank USA (U.S.), Cryoviva Biotech Pvt. Ltd (India), Genecord (U.S.), AlphaCord (U.S.), FamilyCord (U.S.), Cells4Life (UK), Michigan Blood (U.S.), CariCord (U.S.), LifeCell International Pvt. Ltd (India), Stem Cell Cryobank Inc. (U.S.), Viacord Processing Laboratory (VPL) (U.S.), New Jersey Cord Blood Bank (U.S.), Carter BloodCare (U.S.), Americord Registry (U.S.), and others.

Segmentation

The global cord blood banking services market has been segmented on the basis of storage service, component, application, and end-user.

On the basis of storage service, the global cord blood banking services market can be segmented into public cord blood banks, private cord blood banks, and hybrid cord blood banks.

On the basis of application, the global cord blood banking services market can be segmented into cancers, blood disorders, metabolic disorders, immune disorders, and osteoporosis.

On the basis of component, the global cord blood banking services market can be segmented into cord blood, cord tissue, placenta, and others.

On the basis of end-user, the global cord blood banking services market is segmented into hospitals (medical applications), pharmaceutical research (drug discovery), research institutes (scientific research), and others.

Regional Analysis                     

The global cord blood banking services market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global cord blood banking services market owing to the growing number of service providers, increasing awareness about the long-term benefits of cord blood storage, growing investments in public banking, and reduction in the cost involved in storage. Moreover, the U.S. contributes to a significant market share for the global cord blood banking industry. Factors such growing per capita income, increasing number of storage service providers, and high adoption rate for advanced technologies attributed to the largest market share.

The European cord blood banking services market is the second largest market followed by the Asia Pacific region. The Asia Pacific region is expected to dominate the global cord blood banking services market in terms of growth rate during the forecast period. Though the region presently grasps a minimal share in the global market; it is anticipated to exhibit an enormous growth potential owing to the increasing awareness of stem cell banking and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China. Besides, Asia Pacific is a relatively untapped regional market in comparison with developed regions, which is also a reason why it grants better opportunities for the growth of companies.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.

Access More Details of the Report @ https://www.marketresearchfuture.com/reports/cord-blood-banking-services-market-5817